About Mersana Therapeutics
Mersana, an equity-backed private company, is using its proprietary nanotechnology platform to transform existing and experimental anticancer agents into new, patentable drugs with improved pharmaceutical properties. The key component of Mersana's platform is Fleximer(TM), a novel, biodegradable and biologically inert material that can be chemically linked to small molecules and biologics. Mersana's pipeline includes XMT-1001, a Fleximer- camptothecin conjugate currently in Phase I clinical trials, and several preclinical oncology compounds. Mersana's investors include Fidelity Biosciences, ProQuest Investments, Rho Ventures, Harris & Harris Group and PureTech Ventures.
Note: This article has been translated using a computer system without human intervention. LUMITOS offers these automatic translations to present a wider range of company presentation. Since this article has been translated with automatic translation, it is possible that it contains errors in vocabulary, syntax or grammar. The original article in German can be found here.
- Industry : Pharma
